When Do Generics Challenge Drug Patents?

Journal of Empirical Legal Studies

Volumn 8, Issue 4, 2011, Pages 613-649

  Hemphill, C Scott ^a   Sampat, Bhaven N ^b  

^a Columbia Law School ^*  (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859817826     PISSN: 17401453     EISSN: 17401461     Source Type: Journal    
DOI: 10.1111/j.1740-1461.2011.01235.x     Document Type: Article

References (56)

1. Allison, Paul D. (1982) "Discrete-Time Methods for the Analysis of Event Histories, " 13 Sociological Methodology 61.
2. Arrow, Kenneth J. (1962) "Economic Welfare and the Allocation of Resources for Inventions, " in R. R. Nelson, ed., Rate and Direction of Inventive Activity: Economic and Social Factors. Princeton, NJ: Princeton Univ. Press.
3. Berndt, Ernst R., Richard Mortimer, & Andrew Parece (2007) Do Authorized Generic Drugs Deter Paragraph IV Certifications? Recent Evidence. Working Paper. Cambridge, MA: Analysis Group.
4. Bessen, James, & Michael J. Meurer (2008) Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk. Princeton, NJ: Princeton Univ. Press.
5. Bulow, Jeremy (2004) "The Gaming of Pharmaceutical Patents, " in A. B. Jaffe, J. Lerner, & S. Stern, eds, Innovation Policy and the Economy, pp. 145-87. Cambridge, MA: MIT Press.
6. Bureau of Labor Statistics (BLS) (2010) CPI Inflation Calculator. Available at .
7. Cohen, Wesley M., Richard Nelson, & John Walsh (2000) Protecting Their Intellectual Assets: Appropriablity Conditions and Why U.S. Manufactory Firms Patent (or Not). National Bureau of Economic Research Working Paper 7552.
8. DiMasi, Joseph A., Ronald W. Hansen, & Henry G. Grabowski (2003) "The Price of Innovation: New Estimates of Drug Development, " 22 J. of Health Economics 151.
9. Eisenberg, Rebecca S. (2007) "The Role of the FDA in Innovation Policy, " 13 Michigan Telecommunications & Technology Rev. 345.
10. Engelberg, Alfred B. (1999) "Special Patent Provisions for Pharmaceuticals: Have They Outlived Their Usefulness?" 39 IDEA: The J. of Law & Technology 389.
11. Engelberg, Alfred B., Aaron S. Kesselheim, & Jerry Avorn (2009) "Balancing Innovation, Access and Profits: Market Exclusivity for Biologics, " New England J. of Medicine. Available at .
12. Farrell, Joseph, & Robert P. Merges (2004) "Incentives to Challenge and Defend Patents: Why Litigation Won't Reliably Fix Patent Office Errors and Why Administrative Patent Review Might Help, " 19 Berkeley Technology Law J. 943.
13. Federal Trade Commission (FTC) (2002) Generic Drug Entry Prior to Patent Expiration. Washington, DC: Federal Trade Commission.
14. Federal Trade Commission (FTC)(2009) Authorized Generics: An Interim Report. Washington, DC: Federal Trade Commission.
15. Filson, Darren, & Ahmed Oweis (2010) "The Impacts of the Rise of Paragraph IV Challenges on Startup Alliance Formation and Firm Value in the Pharmaceutical Industry, " 29 J. of Health Economics 575.
16. Food and Drug Administration (FDA) (19852009) The Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Washington, DC: Food and Drug Administration.
17. Food and Drug Administration (FDA)(2003a) "Requirements for Submission of In Vivo Bioequivalence Data, " 68 Federal Register 640.
18. Food and Drug Administration (FDA)(2003b) Guidance for Industry: 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day. Available at .
19. Food and Drug Administration (FDA)(2008) Guidance for Industry: Submission of Patent Information for Certain Old Antibiotics. Available at .
20. Food and Drug Administration (FDA)(2009) Drugs@FDA. Available at .
21. Food and Drug Administration (FDA)(2010) Paragraph IV Certifications as of January 11, 2010. Available at .
22. Frank, Richard G. (2007) "The Ongoing Regulation of Generic Drugs, " 357 New England J. of Medicine 1993.
23. Goodman, Marc, Gary Nachman & Louise Chen. (2004) "Quantifying the Impact from Authorized Generics" Morgan Stanley Research Report.
24. Grabowski, Henry G. (2004) "Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures, " 22(Supp. 2) PharmcoEconomics 15.
25. Grabowski, Henry G., & Margaret Kyle (2007) "Generic Competition and Market Exclusivity Periods in Pharmaceuticals, " 28 Managerial & Decision Economics 491.
26. Hall, Bronwyn H., & Rosemary Ham Ziedonis (2001) "The Patent Paradox Revisited: An Empirical Study of Patenting in the U.S. Semiconductor Industry, " 32 Rand J. of Economics 101.
27. Hegde, Deepak, & Bhaven N. Sampat (2009) "Applicant Citations, Examiner Citations, and the Private Value of Patents, " 5(3) Economics Letters 287.
28. Hemphill, C. Scott (2006) "Paying for Delay: Pharmaceutical Patent Settlement as a Regulatory Design Problem, " 81 New York Univ. Law Rev. 1553.
29. Hemphill, C. Scott(2009) "An Aggregate Approach to Antitrust: Using New Data and Rulemaking to Preserve Drug Competition, " 109 Columbia Law Rev. 629.
30. Hemphill, C. Scott, & Bhaven N. Sampat (2011) Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals. Working Paper. Available at .
31. Higgins, Matthew J., & Stuart J. H. Graham (2009) "Balancing Innovation and Access: Patent Challenges Tip the Scales, " 326 Science 370.
32. IMS Health (2009) Economic Analysis of Generic Pharmaceuticals 1999-2008. Available at .
33. Jaffe, Adam, & Josh Lerner (2006) Innovation and Its Discontents: How Our Broken Patent System is Endangering Innovation and Progress, and What to Do About It. Princeton, NJ: Princeton Univ. Press.
34. Jenkins, S. P. (1995a) "Easy Estimation Methods for Discrete-Time Duration Models, " 57 Oxford Bulletin of Economics & Statistics 129.
35. Jenkins, S. P.(1995b) Survival Analysis: The Lecture Notes Manuscript. Available at .
36. Lanjouw, Jean, Ariel Pakes, & Jonathan Putnam (1998) "How to Count Patents and Value Intellectual Property: Uses of Patent Renewal and Application Data, " 46 J. of Industrial Economics 405.
37. Lanjouw, Jean, & Mark Schankerman (2004) "Patent Quality and Research Productivity: Measuring Innovation with Multiple Indicators, " 114 Economic J. 441.
38. Lemley, Mark A. (2001) "Rational Ignorance at the Patent Office, " 95 Northwestern Univ. Law Rev. 1495.
39. Lemley, Mark A., & Bhaven N. Sampat (forthcoming) "Examiner Characteristics and the Patent Grant Rate, " Rev. of Economics & Statistics.
40. Lemley, Mark A., & Carl Shapiro (2005) "Probabilistic Patents, " 19 J. of Economic Perspectives 75.
41. Levin, Richard C., Alvin K. Klevorick, Richard R. Nelson, & Sidney G. Winter (1987) "Appropriating the Returns from Industrial Research and Development, " 3 Brookings Papers on Economic Activity (Special Issue) 783.
42. Lichtenberg, Frank R. (2007) "The Impact of New Drugs on U.S. Longevity and Medical Expenditure, 1990-2003, " 97 American Economic Rev. 438.
43. Lichtenberg, Frank R.(2009) "The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978-2004, " 18 Economics of Innovation & New Technology 407.
44. Lichtenberg, Frank R., & Suchin Virabhak (2007) "Pharmaceutical-Embodied Technical Progress, Longevity, and Quality of Life: Drugs as 'Equipment for Your Health', " 28 Managerial & Decision Economics 371.
45. Miller, Joseph Scott (2004) "Building a Better Bounty: Litigation-Stage Rewards for Defeating Patents, " 19 Berkeley Technology Law J. 667.
46. Murphy, Kevin, & Robert Topel (2000) Measuring the Gains from Medical Research: An Economic Approach. Chicago, IL: Univ. of Chicago Press.
47. National Institute for Health Care Management (NIHCM) (2002) Changing Patterns of Pharmaceutical Innovation. Washington, DC: National Institute for Health Care Management.
48. Perett, Stephen (2008) "The Modified-Release Drug Delivery Landscape, " in Michael J. Rathbone etal., eds., Modified-Release Drug Delivery Technology, 2nd ed., vol. 2, pp. 1-16. New York: Informa Healthcare.
49. Posner, Richard A. (2011) "Regulation (Angencies) Versus Litigation (Courts): An Analytical Framework, " in D. Kessler, ed., Regulation vs. Litigation: Perspectives from Economics and Law, pp. 11-26. Cambridge, MA: National Bureau of Economic Research.
50. Reiffen, David, & Michael R. Ward (2005) "Generic Drug Industry Dynamics, " 87 Rev. of Economics & Statistics 37.
51. Roin, Benjamin (2009) "Unpatentable Drugs and the Standards of Patentability, " 87 Texas Law Rev. 503.
52. Sampat, Bhaven N. (2010) "When Do Patent Applicants Search for Prior Art?" 53(2) J. of Law & Economics 399.
53. Scott Morton, Fiona (1999) "Entry Decisions in the Generic Pharmaceutical Industry, " 30 Rand J. of Economics 421.
54. Thomas, John R. (2001) "Collusion and Collective Action in the Patent System: A Proposal for Patent Bounties, " 2001 Univ. of Illinois Law Rev. 305.
55. Thomas, John R.(2005) Pharmaceutical Patent Law. Washington, DC: BNA Books.
56. Voet, Martin A. (2005) The Generic Challenge: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management. Boca Raton, FL: Brown Walker Press.